Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK enters agreement to acquire IDRx, Inc.
Acquisition adds to GSK’s growing portfolio in gastrointestinal (GI) cancers
Download (PDF, 159.1KB) -
GSK’s Nucala (mepolizumab) approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps
This is the third indication for mepolizumab in China for an IL-5 mediated condition
Download (PDF, 193.2KB) -
GSK announces FIRST trial met its primary endpoint of progression free survival in first line advanced ovarian cancer
GSK announces headline results from the FIRST-ENGOT-OV44 phase III trial.
Download (PDF, 213.0KB) -
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives EMA Priority Medicines (PRIME) Designation in relapsed extensive-stage small-cell lung cancer
Regulatory designation based on promising preliminary clinical data.
Download (PDF, 146.9KB) -
Blenrep shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
DREAMM-7 trial shows sustained overall survival benefit for Blenrep (belantamab mafodotin) combination versus daratumumab combination
Download (PDF, 231.4KB) -
US FDA accepts GSK’s submission for the use of Nucala (mepolizumab) in COPD
Nucala could be the first approved biologic with monthly dosing for patients with COPD
Download (PDF, 188.3KB) -
Blenrep (belantamab mafodotin) combination accepted for priority review in China in relapsed/refractory multiple myeloma
Regulatory submission supported by phase III head-to-head DREAMM-7 trial showing statistically significant efficacy.
Download (PDF, 140.2KB) -
GSK and Zhifei revise and extend strategic vaccine collaboration in China
Shingrix collaboration extended to 2034
Download (PDF, 234.2KB) -
ViiV Healthcare shows more than 99% effectiveness in real-world studies for Apretude (cabotegravir long-acting), the only approved long-acting HIV PrEP, in data presented at IDWeek 2024
Studies from OPERA and Trio cohorts provide further real-world evidence.
Download (PDF, 271.8KB) -
Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents
Gepotidacin could be the first in a new class of oral antibiotic treatment for uUTIs in over 20 years.
Download (PDF, 206.3KB) -
GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps
Depemokimab is an ultra-long-acting biologic administered once every six months
Download (PDF, 199.1KB) -
GSK and ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024
60 abstracts to be presented across broad and growing portfolio of vaccines and medicines aimed at getting ahead of infectious disease.
Download (PDF, 314.0KB) -
Statement: Zantac (ranitidine) litigation – settlement agreements reached
GSK to resolve 93% (approximately 80,000 cases) of U.S. state court Zantac product liability cases for up to $2.2 billion.
Download (PDF, 130.6KB) -
GSK presents positive data for Arexvy, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons
GSK’s RSV vaccine is the only RSV vaccine with efficacy and safety data available through 3 full seasons.
Download (PDF, 175.4KB) -
ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries
At least two million doses of long-acting cabotegravir for PrEP to be made available in 2025-2026.
Download (PDF, 99.2KB) -
GSK’s Menveo meningococcal vaccine in new single-vial, fully liquid presentation receives positive European CHMP opinion
Marketing authorisation in EU expected by November 2024.
Download (PDF, 176.5KB) -
Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple myeloma accepted for regulatory review in Japan
Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials.
Download (PDF, 204.8KB) -
Blenrep (belantamab mafodotin) in combination receives Breakthrough Therapy Designation in China for treatment of relapsed/refractory multiple myeloma
Granted based on results from phase III head-to-head DREAMM-7 trial.
Download (PDF, 136.8KB) -
GSK announces positive headline data from phase II seasonal influenza mRNA vaccine programme
Data support progression to phase III clinical trials.
Download (PDF, 128.7KB) -
GSK provides update on phase I/II therapeutic herpes simplex virus (HSV) vaccine trial
Results show that GSK3943104 did not meet the study’s primary efficacy objective.
Download (PDF, 121.3KB)
